ziltivekimab, Placebo (ziltivekimab C)
NN6018-4914
Phase 3 small_molecule active
Quick answer
ziltivekimab, Placebo (ziltivekimab C) for Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active